In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients
Authors:
- Vincenzo PanichiVPVincenzo Panichi
- Sabrina PaolettiSPSabrina Paoletti
- Emanuela MantuanoEMEmanuela Mantuano
- Giovanni Manca-RizzaGMGiovanni Manca-Rizza
- Cristina FilippiCFCristina Filippi
- Samuele SantiSSSamuele Santi
- Daniele TaccolaDTDaniele Taccola
- Carlo DonadioCDCarlo Donadio
- Gianfranco TramontiGTGianfranco Tramonti
- Maurizio InnocentiMIMaurizio Innocenti
- Giuseppe CastoGCGiuseppe Casto
- Cristina ConsaniCCCristina Consani
Open Access
- 5 October 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 21 (2) , 337-344
Abstract
Background. The beneficial effects of statins in reducing cardiovascular events have been attributed predominantly to their lipid-lowering effects, recent studies suggest that these effects might be due to their anti-inflammatory properties. We here investigate the in vivo and in vitro effects of simvastatin on cytokine production in pre-dialysis chronic renal failure patients. Methods. Our clinical study has been designed as a randomized double-blind placebo controlled study. A total of 55 chronic kidney disease (CKD) patients at stages 3 and 4 (mean creatinine clearance 45 ml/min, range 15–60) were randomly assigned to receive simvastatin 40 mg/day or placebo, added to their ongoing treatment, for 6 months. Blood samples were obtained at baseline, and after 3 and 6 months of observation for the determination of lipids, inflammatory markers and renal function. For the in vitro studies, the effect of increasing doses of simvastatin on cytokine production [namely interleukin (IL)-6 and IL-8] in human cultured monocytes from 10 healthy subjects (HS) and 15 CKD patients stimulated by lipopolysaccharide (LPS) was investigated. Results. A significant reduction in total cholesterol from 221±44 mg/dl to 184±41 mg/dl (3 months) and to 186±39 mg/dl (6 months) (PPP = 0.03) at 6 months (PP = 0.001) at 6 months was also observed. No significant reduction in inflammatory markers [CRP from 5.1 mg/l (IQR 1.9) to 5.4 mg/l (IQR 1.3) (P = NS) at 6 months] or plasma lipids [LDL-cholesterol from 127±32 mg/dl to 131±21 mg/dl (6 months)] was observed in the 27 patients of the placebo group. In the in vitro studies, the average value for cell-associated IL-6 and IL-8 was higher in CKD (155±95 pg/ml monocytes for IL-6 and 722±921 pg/ml monocytes for IL-8) vs HS (137±87 pg/ml monocytes and 186±125 pg/ml monocytes) (PPConclusions. These results indicate that simvastatin in commonly used doses has an in vitro and in vivo anti-inflammatory effect in CKD patients, and may play an important role in counteracting the mechanisms involved on the pathogenesis of cardiovascular disease.Keywords
This publication has 20 references indexed in Scilit:
- Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patientsNephrology Dialysis Transplantation, 2004
- Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharideCoronary Artery Disease, 2003
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patientsKidney International, 2002
- Peripheral blood mononuclear cell production of interleukin-8 and IL-8-dependent neutrophil function in hypercholesterolemic patientsAtherosclerosis, 1999
- Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell lineInternational Journal of Immunopharmacology, 1996
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986